SPEAR UltraDetect™ GFAP Biomarker Assay Kit
The SPEAR UltraDetect™ GFAP Biomarker Assay Kit is an ultra-precise, wash-free assay for glial fibrillary acidic protein, ideal for CNS and neurotrauma research. Requires SPEAR UltraDetect™ Reaction Kit. For research use only.
Receive your quote directly from the manufacturer.
A versatile biomarker for neuroinflammation across neurological conditions
Glial Fibrillary Acidic Protein (GFAP) is a structural protein primarily expressed by astrocytes in the central nervous system (CNS). As a key biomarker of neuroinflammation, elevated levels of GFAP in blood or cerebrospinal fluid (CSF) reflect astrocyte activation or injury, commonly associated with neurodegenerative disease, traumatic brain injury, stroke, and multiple sclerosis (MS). In Alzheimer’s disease (AD), blood GFAP levels have been shown to correlate with amyloid burden, with growing evidence supporting its potential for GFAP as an early indicator of early-stage AD.
Unparalleled Precision with the SPEAR UltraDetect GFAP Assay Kit
SPEAR UltraDetect GFAP demonstrates unparalleled precision. Combined with 100% quantification of healthy samples, high precision is important for detected small changes in longitudinal and clinical trial studies.
Confirming this performance with clinical samples – including healthy controls and diseased patient samples, the SPEAR UltraDetect GFAP assay quantified 100% of samples and achieved a mean replicate CV% of 3.0%
